Primary Cutaneous Anaplastic Large Cell Lymphoma

Also known as: Cutaneous Anaplastic Large Cell Lymphoma / Primary cutaneous CD30-positive T-cell proliferations / Primary cutaneous anaplastic large cell lymphoma (disorder) / Anaplastic large-cell lymphoma, primary cutaneous type / Primary cutaneous anaplastic large T-cell lymphoma, CD30-positive (morphologic abnormality) / Primary cutaneous CD30+ large T-cell lymphoma (disorder) / Lymphoma, Primary Cutaneous Anaplastic Large Cell / Primary cutaneous CD30 antigen positive T-cell lymphoproliferative disorder (disorder) / Primary cutaneous CD30+ T-cell lymphoproliferative disorder (morphologic abnormality)

DrugDrug NameDrug Description
DB08870Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
DrugDrug NamePhaseStatusCount
DB06769Bendamustine1Recruiting1
DB00307Bexarotene1Completed1
DB01073Fludarabine1Recruiting1
DB05527Pralatrexate1Completed1
DB08870Brentuximab vedotin2Active Not Recruiting2
DB00480Lenalidomide2Active Not Recruiting1
DB00307Bexarotene3Completed1
DB08870Brentuximab vedotin3Completed1
DB00563Methotrexate3Completed1